• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    AnaptysBio, Inc. - Common Stock (NQ:ANAB)

    46.81 -1.67 (-3.44%)
    Streaming Delayed Price Updated: 11:20 AM EST, Jan 2, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 134,259
    Open 48.28
    Bid (Size) 46.63 (100)
    Ask (Size) 46.98 (200)
    Prev. Close 48.48
    Today's Range 46.53 - 48.57
    52wk Range 12.21 - 52.47
    Shares Outstanding 27,433,359
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    AnaptysBio Inc (NASDAQ:ANAB) Meets Minervini Trend Template with High-Growth Momentum ↗
    AnaptysBio (ANAB) meets the Minervini Trend Template, showing a powerful technical uptrend backed by accelerating earnings and revenue growth momentum. 
    Via Chartmill
    News headline image
    Anaptys Announces Participation in December Investor Conferences
    From AnaptysBio, Inc.
    Via GlobeNewswire

    Performance

    YTD
    N/A
    N/A
    1 Month
    +14.4%
    +14.4%
    3 Month
    +49.4%
    +49.4%
    6 Month
    +97.1%
    +97.1%
    1 Year
    +250.4%
    +250.4%

    More News

    Read More
    News headline image
    AnaptysBio Inc (NASDAQ:ANAB) Screens as a High-Growth Momentum Leader ↗
    Via Chartmill
    ANAB Stock Falls After It Sues GSK Unit Tesaro Again, Claims Fresh Breach Of 2014 Deal ↗
    Via Stocktwits
    Topics Lawsuit
    News headline image
    Anaptys Announces $100 Million Stock Repurchase Plan
    From AnaptysBio, Inc.
    Via GlobeNewswire
    AnaptysBio Stock Gets A Price Target Hike After Announcing Plan To Separate Royalty, Biopharma Businesses – Check Out The New Level ↗
    Via Stocktwits
    News headline image
    Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary
    From AnaptysBio, Inc.
    Via GlobeNewswire
    News headline image
    ANAPTYSBIO INC (NASDAQ:ANAB) Shows High-Growth Momentum and Positive Technical Setup ↗
    Via Chartmill
    News headline image
    AnaptysBio To Save $10 Million After Discontinuing Ulcerative Colitis Study ↗
    Via Benzinga
    News headline image
    Why AnaptysBio Stock Plummeted, Reversing A 70% Monthlong Run ↗
    Via Investor's Business Daily
    Why Is Eli Lilly’s Stock Slipping Premarket? ↗
    Via Stocktwits
    News headline image
    Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis
    From AnaptysBio, Inc.
    Via GlobeNewswire
    News headline image
    Anaptys Announces Participation in November Investor Conferences
    From AnaptysBio, Inc.
    Via GlobeNewswire
    News headline image
    Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update
    From AnaptysBio, Inc.
    Via GlobeNewswire
    News headline image
    Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation
    From AnaptysBio, Inc.
    Via GlobeNewswire
    News headline image
    Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025
    From AnaptysBio, Inc.
    Via GlobeNewswire
    News headline image
    Wall Street Climbs Despite Shutdown Risk — Pfizer and CoreWeave Shine Bright ↗
    Via Chartmill
    Topics Artificial Intelligence
    News headline image
    Here are the top movers in Tuesday's session. ↗
    Via Chartmill
    News headline image
    AnaptysBio Charts Path To Split Into Two Public Companies By 2026 ↗
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
    Via Benzinga
    News headline image
    United Natural Foods Posts Upbeat Results, Joins AnaptysBio, Semtech, UiPath And Other Big Stocks Moving Higher On Tuesday ↗
    Via Benzinga
    News headline image
    Tuesday's session: gap up and gap down stocks ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Monday's After-Market Session ↗
    Via Benzinga
    News headline image
    Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026
    From AnaptysBio, Inc.
    Via GlobeNewswire
    News headline image
    Anaptys to Provide Overview of ANB033, a CD122 antagonist, at Virtual Investor Event on Tuesday, Oct. 14
    From AnaptysBio, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is AnaptysBio, Inc. - Common Stock publicly traded?
    Yes, AnaptysBio, Inc. - Common Stock is publicly traded.
    What exchange does AnaptysBio, Inc. - Common Stock trade on?
    AnaptysBio, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for AnaptysBio, Inc. - Common Stock?
    The ticker symbol for AnaptysBio, Inc. - Common Stock is ANAB on the Nasdaq Stock Market
    What is the current price of AnaptysBio, Inc. - Common Stock?
    The current price of AnaptysBio, Inc. - Common Stock is 46.81
    When was AnaptysBio, Inc. - Common Stock last traded?
    The last trade of AnaptysBio, Inc. - Common Stock was at 01/02/26 11:20 AM ET
    What is the market capitalization of AnaptysBio, Inc. - Common Stock?
    The market capitalization of AnaptysBio, Inc. - Common Stock is 1.28B
    How many shares of AnaptysBio, Inc. - Common Stock are outstanding?
    AnaptysBio, Inc. - Common Stock has 1B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.